Connect Biopharma (NASDAQ:CNTB) Rating Increased to Strong-Buy at Northland Capmk

Connect Biopharma (NASDAQ:CNTB - Get Free Report) was upgraded by stock analysts at Northland Capmk to a "strong-buy" rating in a report released on Tuesday,Zacks.com reports.

Separately, HC Wainwright assumed coverage on Connect Biopharma in a report on Thursday, June 12th. They issued a "buy" rating and a $7.00 price objective on the stock.

Connect Biopharma Price Performance

Connect Biopharma stock opened at $2.38 on Tuesday. Connect Biopharma has a one year low of $0.51 and a one year high of $2.86. The business has a fifty day moving average price of $0.99 and a 200-day moving average price of $0.90. The company has a quick ratio of 10.25, a current ratio of 10.25 and a debt-to-equity ratio of 0.01.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. As a group, equities analysts anticipate that Connect Biopharma will post -0.22 EPS for the current year.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.